“The third quarter of 2023 was a period of considerable progress for Cognition, with significant clinical development milestones in our Alzheimer’s disease pipeline: advancing enrollment in our Phase 2 SHINE trial for people with mild-to-moderate Alzheimer’s disease and initiation of recruitment in our Phase 2 START trial, for which we amended the trial protocol to include patients with early Alzheimer’s disease who are being treated with lecanemab,” commented Lisa Ricciardi, president and CEO of Cognition Therapeutics. “We believe these important events, in addition to the data from our SEQUEL EEG study presented at CTAD 2023, position Cognition and CT1812 as a leader in the innovative Alzheimer’s landscape.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CGTX:
- Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD
- Cognition, Yale collaborators, ACTC announce presentation on START study
- Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD
- Cognition Therapeutics presents new data at CTAD conference